September 2025 - Desert King

Responsible Management: Desert King leads quillay traceability and sustainable management with FSC® certification The company is the only one in the quillay industry to hold FSC® Chain of [...]

By Desert King

Posted 15 September, 2025

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China. Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the [...]

By Desert King

Posted 15 September, 2025

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192. PMID: 40804241 This study supports a [...]

By Desert King

Posted 15 September, 2025

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30. PMID: 40737310 LeishTec is a recombinant vaccine adjuvanted [...]

By Desert King

Posted 15 September, 2025

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396. PMID: 40592255 This study [...]

By Desert King

Posted 15 September, 2025

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, [...]

By Desert King

Posted 15 September, 2025

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, [...]